Pfizer is a global biopharmaceutical company that primarily provides medicines and vaccines addressing a range of diseases. Its main product categories include internal medicine, vaccines, inflammation and immunology, rare diseases, and oncology. Pfizer operates through three segments: Biopharma, which is the main segment, PC1 for contract development and manufacturing, and Pfizer Ignite, which offers R&D services to biotech firms.
Pfizer generates revenue through the sale of its biopharmaceutical products, with significant contributions from international markets such as China and Japan. The company's primary customers include wholesalers, hospitals, and government agencies, with vaccines often sold directly to the U.S. federal government and other international institutions. Pfizer's revenue is impacted by competition from generic and biosimilar manufacturers, pricing pressures from managed care organizations, and patent expirations.
Pfizer's operational structure includes divisions for oncology, U.S. commercial operations, and international commercial operations. Key factors impacting its business performance include competition, patent expirations, pricing and reimbursement challenges, and regulatory compliance. The company actively manages its R&D pipeline, focusing on enhancing existing products and discovering new indications through both internal efforts and external collaborations.